Abstract of invention (Not applicable in case of provisional specification. Separate sheet to be used for this column.)e antiurolithiatic activity of a polyherbal formulation, Unex. Urolithiasis or form The present invention relates to thation of urinary calculi at any level of the urinary tract is a common condit...

Described is novel oral dosage form for administration of an extract of (i) Withania somnifera Dunal. extract preferably taken as percentage of total final composition in the range of 0.1% to 10% more preferably to 1.6%, (ii) Bacopa monnieri Linn, extract preferably taken as percentage of total final composition in ...

Described is novel oral dosage form for administration of an extract of (i) Boswellia serrata Roxb. ex Colebr., preferably taken, as percentage of total final composition, in a range of about 5 to 50%, more preferably to about 26%, (ii) Vitex negundo Linn, preferably taken, as percentage of total final composition, ...

Described is novel oral dosage form for administration of an extract of (i) Holarrhena antidysenterica (Roth) A. DC. extract preferably taken as percentage of total final composition in the range of 2% to 20% more preferably to 9.6%, and (ii) Euphorbia hirta Linn, extract preferably taken as percentage of total fina...

Described is novel oral dosage form for administration of an extract of (i) Picrorhiza kurroa Royle ex Benth. extract preferably taken as percentage of total final composition in the range of 0.1% to 10% more preferably to 1.11%, and (ii) Phyllanthus niruri Linn, extract preferably taken as percentage of total final...

Described is novel oral dosage form for administration of an extract of (i) Bacopa monnieri Linnpreferably taken, as percentage of total final composition, in a range of 0.1 to 10%, more preferably to 2.88%, and (ii) Centella asiatica Linn, preferably taken, as percentage of total final composition, in a range of 0....

Described is novel oral dosage form for administration of an extract of (i) Zingiber officinale Roxb., preferably taken, as percentage of total final composition, in a range of about 0.2 to 8% more preferably to about 3.33% %, and (ii) Piper iongum Linn., preferably taken in a range of about 0.5 to 15 %, more prefer...

Described is novel oral dosage form for administration of an extract of (i) Cassia angustifolia Vahl. extract preferably taken as percentage of total final composition in the range of 0.5% to 15% more preferably to 3.44%, (ii) Glycyrrhiza glabra Linn, extract preferably taken as percentage of total final composition...

Described is novel oral dosage form for administration of one or more of an extract of (i) An extract of Tribulus terrestris Linn, extract preferably taken as percentage of total final composition in the range of 5% to 30% more preferably to 21.25%, and (ii) Terminalia arjuna W. and A. extract preferably taken as pe...

Described is novel oral dosage form for administration of an extract of (i) Tribulus terrestris Linn, extract preferably taken as percentage of total final composition in the range of 0.1% to 10% more preferably to 1.6%, and (ii) Mucuna prureins Baker, extract preferably taken as percentage of total final compositio...

Described is novel oral dosage form for administration of an extract of (i) Boerhavia diffusa Linn, extract preferably taken as percentage of total final composition in the range of 2% to 20% more preferably to 9.16%, and (v) Tribulus terrestris Linn, extract preferably taken as percentage of total final composition...

Described is novel oral dosage form for administration of one or more of an herbal extract and process for preparing the same wherein a herbal extract is coated on pellets and the said pellets are either filled into a capsule or compressed into a tablet, the said capsule may contain pellets coated with one or more o...

The invention comprises an oral film, single layer or multilayer, for delivering an active ingredients, herbal or non-herbal, to oral cavity, wherein the said oral film requires at least a delay of about 5 seconds after coming in contact with oral lnucosa to stick to the mucosa surface in contact and rapidly dissolv...

Described is novel oral dosage form for administration of an extract of (i) Asparagus racemosus Willd. extract preferably taken as percentage of total final composition in the range of 0.5% to 15% more preferably to 3.4%, (ii) Allium sativum Linn, extract preferably taken as percentage of total final composition in ...

Described is novel oral dosage form for administration of one or more of an herbal extract and process for preparing the same wherein a herbal extract is coated on pellets and the said pellets are either filled into a capsule or compressed into a tablet, the said capsule may contain pellets coated with one or more o...

The invention comprises an oral film, single layer or multilayer, for delivering an active ingredients, herbal or non-herbal, to oral cavity, wherein the said oral film requires at least a delay of about 5 seconds after coming in contact with oral mucosa to stick to the mucosa surface in contact and rapidly dissolve...